Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34⁺ Cells for Clinical Use After Myocardial Infarction.

ABSTRACT: We previously demonstrated that intracardiac delivery of autologous peripheral blood-derived CD34⁺ stem cells (SCs), mobilized by granulocyte-colony stimulating factor (G-CSF) and collected by leukapheresis after myocardial infarction, structurally and functionally repaired the damaged myocardial area. When used for cardiac indication, CD34⁺ cells are now considered as Advanced Therapy Medicinal Products (ATMPs). We have industrialized their production by developing an automated device for ex vivo CD34⁺ -SC expansion, starting from a whole blood (WB) sample. Blood samples were collected from healthy donors after G-CSF mobilization. Manufacturing procedures included: (a) isolation of total nuclear cells, (b) CD34⁺ immunoselection, (c) expansion an

SUBMITTER: Saucourt C 

PROVIDER: S-EPMC6646685 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature